Antonella Brunello

Dr. Antonella Brunello

Istituto Oncologico Veneto IOV-IRCCS
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2013 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
FLF. Lumachi
F. Lumachi
Antonella BrunelloAntonella Brunello
Antonella Brunello
MMMarco Maruzzo
Marco Maruzzo
UBUmberto Basso
Umberto Basso
SBS. M.M. Basso
S. M.M. Basso
Estrogen receptor (ER) expression is the main indicator of potential responses to endocrine therapy (ET), and approximately 70% of human breast cancers (BCs) are hormone-dependent and ER-positive. The introduction of adjuvant systemic therapy led to a significant improvement in post-surgical survival and a reduction in disease relapse, especially in women with early BC and those with ER+ tumors, who may receive ET alone or in combination with cytotoxic therapy. Adjuvant ET currently consists of (i) ovarian suppression, (ii) selective estrogen receptor modulators (SERMs) and down-regulators, and (iii) aromatase inhibitors (AIs). In patients with ER+ tumors pharmacologic ovary suppression with gonadotropin-releasing hormone agonists in combination with standard adjuvant therapy is generally more effective than adjuvant chemotherapy alone. Tamoxifen is the best established SERM, has favorable effects on BC control and bone metabolism, but also has adverse effects due to its estrogenic activity in other tissues. For these reasons, other SERMs have been developed. Fulvestrant is an ER down-regulator with several potential advantages over SERMs, including a 100-fold increase in its affinity for ER compared with tamoxifen and no estrogen-like activity in the uterus. The inhibition of the aromatase system with third-generation AIs is associated with improved survival in patients with advanced BC compared with SERMs. In postmenopausal patients with ER+ BC adjuvant treatment with AIs should be performed, either as sequential treatment after tamoxifen or as upfront therapy. Studies evaluating the role of AIs as first-line therapy are ongoing and the results are encouraging.

1 February 2011 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
FLF. Lumachi
F. Lumachi
GLG. Luisetto
G. Luisetto
SBS. M.M. Basso
S. M.M. Basso
UBUmberto Basso
Umberto Basso
Antonella BrunelloAntonella Brunello
Antonella Brunello
VCV. Camozzi
V. Camozzi
Breast cancer remains one of the first leading causes of death in women, and currently endocrine treatment is of major therapeutic value in patients with estrogen-receptor positive tumors. Selective estrogen-receptor modulators (SERMs), such as tamoxifen and raloxifene, aromatase inhibitors, and GnRH agonists are the drugs of choice. Tamoxifen, a partial nonsteroidal estrogen agonist, is a type II competitive inhibitor of estradiol at its receptor, and the prototype of SERMs. Aromatase inhibitors significantly lower serum estradiol concentration in postmenopausal patients, having no detectable effects on adrenocortical steroids formation, while GnRH agonists suppress ovarian function, inducing a menopause- like condition in premenopausal women. Endocrine therapy has generally a relatively low morbidity, leading to a significant reduction of mortality for breast cancer. The aim of chemoprevention is to interfere early with the process of carcinogenesis, reducing the risk of cancer development. As preventive agents, raloxifene and tamoxifene are equivalent, while raloxifene has more potent antiresorptive effects in postmenopausal osteoporosis. Endocrine treatment is usually considered a standard choice for patients with estrogen-receptor positive cancers and non-life-threatening advanced disease, or for older patients unfit for aggressive chemotherapy regimens. Several therapeutic protocols used in patients with breast cancer are associated with bone loss, which may lead to an increased risk of fracture. Bisphosphonates are the drugs of choice to treat such a drug-induced bone disease. The aim of this review is to outline current understanding on endocrine therapy of breast cancer.

1 July 2014 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
MPMihaela A. Popa
Mihaela A. Popa
KWKristie J. Wallace
Kristie J. Wallace
Antonella BrunelloAntonella Brunello
Antonella Brunello
MEMartine Extermann
Martine Extermann
LBLodovico Balducci
Lodovico Balducci

13 October 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
SPSandro Pasquali
Sandro Pasquali
Emanuela PalmeriniEmanuela Palmerini
Emanuela Palmerini
VQVittorio Quagliuolo
Vittorio Quagliuolo
Javier Martin-BrotoJavier Martin-Broto
Javier Martin-Broto
ALAntonio Lopez‐Pousa
Antonio Lopez‐Pousa
AGAlessandro Gronchi
Alessandro Gronchi

1 January 2009 in Bone
Verified
Journal Article
Closed access
Antonella BrunelloAntonella Brunello
Antonella Brunello
GSGiorgia Saia
Giorgia Saia
Alberto BedogniAlberto Bedogni
Alberto Bedogni
DSDaniela Scaglione
Daniela Scaglione
UBUmberto Basso
Umberto Basso

1 June 2011 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
Antonella BrunelloAntonella Brunello
Antonella Brunello
RKRachna Mbbs Kapoor
Rachna Mbbs Kapoor
MEMartine Extermann
Martine Extermann
Background: Few data are available concerning how glycemic control can affect outcomes in cancer patients treated with chemotherapy. Methods: Charts of non-Hodgkin lymphoma (NHL) and prostate cancer (PC) patients treated at Moffitt Cancer Center between January 1999 and September 2006 were reviewed, and patients who received cyclophosphamide, doxoruicin, vincristine, prednisone, rituximab or Docetaxel plus steroids were eligible. Demographics, vitals, comorbidity, laboratory parameters including baseline and average glucose level during chemotherapy, G4 hematological toxicity (HemT), and G3–G4 non-hematological toxicity (NHemT), progression, and death dates were recorded. Results: A total of 349 patients were eligible (NHL/PC: 162/187). G4 HemT was experienced by 76 (47%) NHL and 9 (5%) PC patients. Seventy-nine NHL and 90 PC patients had G3–G4 NHemT. The most frequent NHemT were as follows: neuropathy (25.3%), fever (non-neutropenic, 18.9%), fatigue (15.2%), for NHL; and fatigue (22.1%), thromboembolic events (11.6%), and diarrhea (9.3%) for PC. For NHL patients, G3–G4 NHemT was associated with baseline hyperglycemia (P = 0.0384, Wilcoxon Rank-Sum test) as well as with average glycemia during chemotherapy (P = 0.0048), whereas there was no significant correlation for HemT. For PC patients, a positive correlation was found between baseline hyperglycemia and G4 HemT (P = 0.0241), while univariate correlations between average glycemia during chemotherapy and G4 HemT and between both baseline and average glycemia with NHemT were not significant, multivariate correlation between average glycemia during chemotherapy and overall severe toxicity was significant at 0.05 level. Conclusions: In NHL patients, hyperglycemia correlates with NHemT, and a similar although less clear pattern is suggested in PC patients. Prospective studies are needed to assess whether a better glycemic control during chemotherapy can improve toxicity and outcomes.